Results 151 to 160 of about 76,259 (245)

A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia. [PDF]

open access: yesHemasphere
Lenti E   +11 more
europepmc   +1 more source

Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes

open access: yesBritish Journal of Haematology, EarlyView.
A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu   +17 more
wiley   +1 more source

Animal Venoms as Potential Antitumor Agents Against Leukemia and Lymphoma. [PDF]

open access: yesCancers (Basel)
Malachias-Pires GM   +9 more
europepmc   +1 more source

Patients With Atopic Dermatitis Show Increased Clonal Hematopoiesis and Risk of Hematological Cancer

open access: yes
Allergy, EarlyView.
Verena Vogi   +6 more
wiley   +1 more source

ZIP10 as a potential therapeutic target in acute myeloid leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Increased intracellular zinc levels in acute myeloid leukaemia blasts with upregulated expression of zinc influx transporters ZIP6 and ZIP10. Targeting ZIP10 with a surface antibody represents a potential therapeutic strategy. Created in BioRender. Rolles, B. (2025) https://BioRender.com/bwrtof1.
Benjamin Rolles   +18 more
wiley   +1 more source

Pleurisy in patients with chronic lymphoid leukemia

open access: yesBulletin Physiology and Pathology of Respiration, 2020
A. A. Sinyuk, V. V. Voytsekhovskiy
openaire   +3 more sources

Synergistic effect of asciminib with reduced doses of ponatinib in human Ph + myeloid leukemia with the T315M mutation. [PDF]

open access: yesInt J Hematol
Nguyen T   +8 more
europepmc   +1 more source

Clusterin and pentraxin 3 are markers of severity during febrile neutropenia in adults with haematological malignancies receiving intensive chemotherapy

open access: yesBritish Journal of Haematology, EarlyView.
During febrile neutropenia in patients with haematological malignancies, pentraxin 3 (PTX3), a soluble innate immunity receptor, increases with severe sepsis, while clusterin, a chaperon protein involved in extracellular histones clearance, decreases in patients with quick SOFA score (qSOFA) ≥2.
Coralie Mallebranche   +13 more
wiley   +1 more source

RETRACTED: Kalicińska et al. Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG). <i>Cancers</i> 2024, <i>16</i>, 4168. [PDF]

open access: yesCancers (Basel)
Kalicińska E   +13 more
europepmc   +1 more source

Clonal haematopoiesis associates with distinct cytometric changes of red blood cells and platelets

open access: yesBritish Journal of Haematology, EarlyView.
Venn diagram illustrating the interrelation between clonal haematopoiesis, elevated mean corpuscular volume/red cell distribution width (MCV/RDW) and blood count abnormalities. The overlap underscores the frequent co‐occurrence of these age‐associated haematopoietic changes. Individuals presenting with all three features demonstrate an elevated risk of
J. B. Salzbrunn   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy